

# Peter Doshi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6130175/publications.pdf>

Version: 2024-02-01

65  
papers

2,011  
citations

361045

20  
h-index

329751

37  
g-index

67  
all docs

67  
docs citations

67  
times ranked

2431  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transparency of COVID-19 vaccine trials: decisions without data. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 199-205.	1.7	39
2	Authors'™ reply to Chiolero, Bannon, and Dickinson. <i>BMJ, The</i> , 2022, 376, o170.	3.0	0
3	Covid-19 vaccines and treatments: we must have raw data, now. <i>BMJ, The</i> , 2022, 376, o102.	3.0	34
4	Evaluation of Publicly Available Information on Sex-Related Differences in the Efficacy and Safety of Newly Approved Medications. <i>Journal of General Internal Medicine</i> , 2022, , 1.	1.3	0
5	Assessing Muscle-Related Adverse Events in Randomized Trials of Statins. <i>Journal of General Internal Medicine</i> , 2022, , 1.	1.3	1
6	Determining the Infectious Potential of Individuals With Positive Reverse-Transcription Polymerase Chain Reaction Severe Acute Respiratory Syndrome Coronavirus 2 Tests. <i>Clinical Infectious Diseases</i> , 2021, 73, e3900-e3901.	2.9	2
7	Control vaccine formulation. <i>Lancet, The</i> , 2021, 397, 1061-1062.	6.3	0
8	Covid-19 vaccines: In the rush for regulatory approval, do we need more data?. <i>BMJ, The</i> , 2021, 373, n1244.	3.0	30
9	The end of the pandemic will not be televised. <i>BMJ, The</i> , 2021, 375, e068094.	3.0	12
10	Evaluating covid-19 vaccine efficacy and safety in the post-authorisation phase. <i>BMJ, The</i> , 2021, 375, e067570.	3.0	5
11	Availability of study protocols for randomized trials published in high-impact medical journals: A cross-sectional analysis. <i>Clinical Trials</i> , 2020, 17, 99-105.	0.7	19
12	Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling. <i>Journal of General Internal Medicine</i> , 2020, 35, 377-379.	1.3	3
13	Will covid-19 vaccines save lives? Current trials aren't designed to tell us. <i>BMJ, The</i> , 2020, 371, m4037.	3.0	78
14	Covid-19 vaccine trial protocols released. <i>BMJ, The</i> , 2020, 371, m4058.	3.0	25
15	Integrated Drug Reviews at the US Food and Drug Administration"Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 1261.	2.6	2
16	Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available?. <i>BMJ, The</i> , 2020, 370, m3260.	3.0	11
17	Incompletely Reported Important Methodological Details and Inaccurate Description of the Formulation That the Control Arms Received in a Gardasil Vaccine Trial. <i>MSphere</i> , 2020, 5, .	1.3	2
18	Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology. <i>BMJ Evidence-Based Medicine</i> , 2020, 25, 213-219.	1.7	7

#	ARTICLE	IF	CITATIONS
19	Statins for primary prevention: what is the regulator's role?. <i>BMJ Evidence-Based Medicine</i> , 2020, , bmjebm-2019-111321.	1.7	3
20	Integrated Drug Reviews at the US Food and Drug Administration—Legal Concerns and Knowledge Lost. <i>JAMA Internal Medicine</i> , 2020, 180, 629.	2.6	8
21	Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19. <i>Journal of Law and the Biosciences</i> , 2020, 7, lsa083.	0.8	5
22	Contradictory Findings on Efficacy of Neuraminidase Inhibitors Not Cited. <i>Journal of Infectious Diseases</i> , 2020, 222, 1578-1579.	1.9	0
23	The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us?. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 195-201.	0.7	0
24	Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 11-19.	2.4	24
25	Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 20-27.	2.4	34
26	Canada finally opens up data on new drugs and devices. <i>BMJ: British Medical Journal</i> , 2019, 365, l1825.	2.4	7
27	Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone. <i>JAMA Internal Medicine</i> , 2019, 179, 719.	2.6	5
28	Neuraminidase inhibitors for preventing and treating influenza in adults and children. <i>The Cochrane Library</i> , 2018, 2018, CD008965.	1.5	328
29	Challenges of independent assessment of potential harms of HPV vaccines. <i>BMJ: British Medical Journal</i> , 2018, 362, k3694.	2.4	13
30	Patient consent to publication and data sharing in industry and NIH-funded clinical trials. <i>Trials</i> , 2018, 19, 269.	0.7	14
31	Restoring biomedical literature with RIAT. <i>BMJ: British Medical Journal</i> , 2018, 361, k1742.	2.4	10
32	The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. <i>Systematic Reviews</i> , 2018, 7, 117.	2.5	24
33	<sc>ADHD</sc> medications and cardiovascular adverse events in children and adolescents: cross-national comparison of risk communication in drug labeling. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 274-284.	0.9	5
34	Findings of an Observational Study of Neuraminidase Inhibitors Highly Sensitive to Decision to Exclude 1652 Treated Patients. <i>Clinical Infectious Diseases</i> , 2017, 65, 1050-1050.	2.9	1
35	Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 95-110.	2.4	83
36	Informed Consent to Study Purpose in Randomized Clinical Trials of Antibiotics, 1991 Through 2011. <i>JAMA Internal Medicine</i> , 2017, 177, 1452.	2.6	22

#	ARTICLE	IF	CITATIONS
37	Disclose Data Publicly, without Restriction. <i>Journal of Law, Medicine and Ethics</i> , 2017, 45, 42-45.	0.4	2
38	Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. <i>BMJ: British Medical Journal</i> , 2017, 356, j337.	2.4	30
39	Is this trial misrepresented? Truth seeking in the burgeoning age of trial transparency. <i>BMJ, The</i> , 2016, 355, i5543.	3.0	2
40	Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency. <i>Trials</i> , 2016, 17, 78.	0.7	26
41	Neuraminidase Inhibitors and Influenza Infection. <i>JAMA Internal Medicine</i> , 2016, 176, 415.	2.6	3
42	Oseltamivir for influenza. <i>Lancet, The</i> , 2016, 387, 124.	6.3	7
43	The Untapped Potential of Pharmacy Leaflets for Informing Patients About Drug Benefits and Risks. <i>JAMA Internal Medicine</i> , 2016, 176, 11.	2.6	5
44	North American regulatory agencies can and should make clinical trial data publicly available. <i>Cmaj</i> , 2016, 188, 96-97.	0.9	8
45	Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. <i>Health Technology Assessment</i> , 2016, 20, 1-242.	1.3	79
46	Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review. <i>Systematic Reviews</i> , 2015, 4, 143.	2.5	15
47	Safety and Efficacy of Inactivated Influenza Vaccines in Children. <i>Clinical Infectious Diseases</i> , 2015, 60, 489-489.	2.9	1
48	Oseltamivir for influenza. <i>Lancet, The</i> , 2015, 386, 1134-1135.	6.3	9
49	Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. <i>BMJ Open</i> , 2014, 4, e005253-e005253.	0.8	20
50	Tamiflu reviewers respond to critics. <i>Nature</i> , 2014, 509, 288-288.	13.7	1
51	Multisystem failure: the story of anti-influenza drugs. <i>BMJ, The</i> , 2014, 348, g2263-g2263.	3.0	50
52	Authors' reply to Dunning. <i>BMJ, The</i> , 2014, 348, g3018-g3018.	3.0	0
53	Digging for data on harms in duloxetine trials. <i>BMJ, The</i> , 2014, 348, g3578-g3578.	3.0	3
54	Neuraminidase inhibitors for influenza complications. <i>Lancet, The</i> , 2014, 384, 1260-1261.	6.3	14

#	ARTICLE	IF	CITATIONS
55	The Importance of Influenza Vaccinationâ€™Reply. JAMA Internal Medicine, 2014, 174, 645.	2.6	0
56	Transparency Interrupted. JAMA Internal Medicine, 2013, 173, 2009.	2.6	9
57	Influenza: marketing vaccine by marketing disease. BMJ, The, 2013, 346, f3037-f3037.	3.0	19
58	Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ, The, 2013, 346, f2865-f2865.	3.0	153
59	The First 2 Years of the European Medicines Agency's Policy on Access to Documents: Secret No Longer. JAMA Internal Medicine, 2013, 173, 380.	2.6	24
60	Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open, 2013, 3, e002496.	0.8	68
61	Influenza Vaccines. JAMA Internal Medicine, 2013, 173, 1014.	2.6	12
62	The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience. PLoS Medicine, 2012, 9, e1001201.	3.9	141
63	Rethinking credible evidence synthesis. BMJ: British Medical Journal, 2012, 344, d7898-d7898.	2.4	54
64	Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. , 2012, 1, CD008965.		383
65	Pandemrix vaccine: why was the public not told of early warning signs?. BMJ: British Medical Journal, 0, , k3948.	2.4	17